Aggressive surgical strategies in advanced ovarian cancer: A monocentric study of 203 stage IIIC and IV patients

European Journal of Surgical Oncology

Volumn 35, Issue 2, 2009, Pages 135-143

  Colombo, P E ^a   Mourregot, A ^a   Fabbro, M ^a   Gutowski, M ^a   Saint Aubert, B ^a   Quenet, F ^a   Gourgou, S ^a   Rouanet, P ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Advanced ovarian cancer; Cytoreductive surgery; Initial surgery; Interval surgery

Indexed keywords

CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FRANCE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 58149489496     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.01.005     Document Type: Article

References (53)

1. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
2. Bhoola S., and Hoskins W.J. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 107 (2006) 1399-1410
3. Griffiths C.T., Parker L.M., and Fuller Jr. A.F. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63 (1979) 235-240
4. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61 (1983) 413-420
5. Delgado G., Oram D.H., and Petrilli E.S. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 18 (1984) 293-298
6. Seifer D.B., Kennedy A.W., Webster K.D., Vanderbrug M.S., and Isakson D.G. Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma. Cleve Clin J Med 55 (1988) 555-560
7. Piver M.S., Lele S.B., Marchetti D.L., Baker T.R., Tsukada Y., and Emrich L.J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 6 (1988) 983-989
8. Sutton G.P., Stehman F.B., Einhorn L.H., Roth L.M., Blessing J.A., and Ehrlich C.E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7 (1989) 223-229
9. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 38 (1990) 203-209
10. Covens A.L. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78 (2000) 269-274
11. Hoskins W.J., Bundy B.N., Thigpen J.T., and Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47 (1992) 159-166
12. Morice P., Brehier-Ollive D., Rey A., et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol 14 (2003) 74-77
13. van der Burg M.E., van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332 (1995) 629-634
14. Fanfani F., Ferrandina G., Corrado G., et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 65 (2003) 316-322
15. Kayikcioglu F., Kose M.F., Boran N., Caliskan E., and Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11 (2001) 466-470
16. Lee S.-J., Kim B.-G., Lee J.-W., Park C.-S., Lee J.-H., and Bae D.-S. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res 32 (2006) 99-106
17. Surwit E., Childers J., Atlas I., et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 6 (1996) 356-361
18. Vergote I., De W.I., Tjalma W., Van Gramberen M., Decloedt J., and van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71 (1998) 431-436
19. Esquivel J., Farinetti A., and Sugarbaker P.H. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed. Geka Chiryo 20 (1999) 81-86
20. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
21. Goldie J.H., and Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63 (1979) 1727-1733
22. Del Campo J.M., Felip E., Rubio D., et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 53 (1994) 27-32
23. Makar A.P., Baekelandt M., Trope C.G., and Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56 (1995) 175-180
24. Scarabelli C., Gallo A., Franceschi S., et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 88 (2000) 389-397
25. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69 (1998) 103-108
26. Tingulstad S., Skjeldestad F.E., Halvorsen T.B., and Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101 (2003) 885-891
27. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90 (2003) 390-396
28. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
29. Eisenkop S.M., and Spirtos N.M. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?. Gynecol Oncol 82 (2001) 435-441
30. Eisenkop S.M., Spirtos N.M., and Lin W.C. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 103 (2006) 329-335
31. Brun J.L., Feyler A., Chene G., Saurel J., Brun G., and Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78 (2000) 21-27
32. Chi D.S., Liao J.B., Leon L.F., et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82 (2001) 532-537
33. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-979
34. Hunter R.W., Alexander N.D., and Soutter W.P. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?. Am J Obstet Gynecol 166 (1992) 504-511
35. Panici P.B., Maggioni A., Hacker N., et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97 (2005) 560-566
36. Crawford S.C., Vasey P.A., Paul J., Hay A., Davis J.A., and Kaye S.B. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 23 (2005) 8802-8811
37. Le T., Krepart G.V., Lotocki R.J., and Heywood M.S. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?. Gynecol Oncol 67 (1997) 208-214
38. Ansquer Y., Leblanc E., Clough K., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91 (2001) 2329-2334
39. Inciura A., Simavicius A., Juozaityte E., et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer 6 (2006) 153-160
40. Kuhn W., Rutke S., Spathe K., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92 (2001) 2585-2591
41. Mazzeo F., Berliere M., Kerger J., et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90 (2003) 163-169
42. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., and Thiel R.P. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72 (1999) 93-99
43. Bristow R.E., and Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103 (2006) 1070-1076
44. Chi D.S., Venkatraman E.S., Masson V., and Hoskins W.J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77 (2000) 227-231
45. Memarzadeh S., Lee S.B., Berek J.S., and Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 13 (2003) 120-124
46. Bristow R.E., Duska L.R., Lambrou N.C., et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89 (2000) 1532-1540
47. Angioli R., Palaia I., Zullo M.A., et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol 100 (2006) 455-461
48. Vergote I.B., De W.I., Decloedt J., Tjalma W., Van Gramberen M., and van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 27 (2000) 31-36
49. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., and Wang H.J. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47 (1992) 203-209
50. Kumpulainen S., Kuoppala T., Leminen A., et al. Surgical treatment of ovarian cancer in different hospital categories - a prospective nation-wide study in Finland. Eur J Cancer 42 (2006) 388-395
51. Aletti G.D., Gostout B.S., Podratz K.C., and Cliby W.A. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100 (2006) 33-37
52. Eisenkop S.M., and Spirtos N.M. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?. Gynecol Oncol 82 (2001) 489-497
53. Eisenkop S.M. Commenting on centralizing surgery for gynecologic oncology: a strategy assuring better quality treatment? (89:4-8) by Karsten Munstedt, et al. Gynecol Oncol 94 (2004) 605-606